The world's top insulin maker, Novo Nordisk, said on Tuesday it would build a 70 million euro ($78 million) facility in Iran, signaling its "long-term commitment" to the country.
"We are happy to commit to this manufacturing facility in Iran," Ole Moelskov Bech, who heads part of the group's Middle East business, said in a statement quoted by the AFP news agency.
(Arutz Sheva’s North American desk is keeping you updated until the start of Yom Kippur in New York. The time posted automatically on all Arutz Sheva articles, however, is Israeli time.)
Read more